Neumora Therapeutics Sees Unusually High Options Volume (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA) was the target of some unusual options trading on Thursday. Stock investors acquired 23,875 call options on the company. This is an increase of 1,102% compared to the average volume of 1,987 call options.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $10.32 on Friday. The stock’s fifty day simple moving average is $12.03 and its 200 day simple moving average is $11.50. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -5.52 and a beta of 3.34. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter last year, the business earned ($1.14) earnings per share. On average, research analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now directly owns 20,100 shares of the company’s stock, valued at $342,303. The trade was a 41.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Robert A. Lenz sold 30,788 shares of Neumora Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. This represents a 8.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,400 shares of company stock valued at $686,361. Corporate insiders own 26.40% of the company’s stock.

Institutional Trading of Neumora Therapeutics

Several institutional investors have recently bought and sold shares of NMRA. Amalgamated Bank boosted its stake in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after buying an additional 2,402 shares in the last quarter. Quarry LP acquired a new position in Neumora Therapeutics in the second quarter worth $98,000. SkyOak Wealth LLC acquired a new position in Neumora Therapeutics in the second quarter worth $147,000. Principal Financial Group Inc. acquired a new position in Neumora Therapeutics in the second quarter worth $166,000. Finally, Intech Investment Management LLC acquired a new position in Neumora Therapeutics in the third quarter worth $175,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on NMRA shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Royal Bank of Canada restated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Friday, November 22nd. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.40.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.